Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient.

31 Jan 2013

Phenformin decreases size of lung tumors and increases survival in mice

Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.

30 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

HDL cholesterol key to fighting lymphoma

High-density lipoprotein cholesterol could provide a novel treatment target for patients with lymphoma, US scientists believe.

25 Jan 2013

Study shows promising results for cancer treatment

The plasma membrane transporter SLC5A8 can inhibit the spread of tumours by decreasing the amount of the anti-apoptotic protein surviving in tumour cells.

25 Jan 2013

BH3-mimetics might be new option for treatment of autoimmune conditions

Melbourne researchers have discovered that the death of immune system cells is an important safeguard against the development of diseases such as type 1 diabetes, rheumatoid arthritis and lupus, which occur when the immune system attacks the body's own tissues.

23 Jan 2013

Stage IV cancer cells even more susceptible to grape seed extract than stage II

When the going gets tough, grape seed extract gets going: A University of Colorado Cancer Center study recently published in the journal Cancer Letters shows that the more advanced are colorectal cancer cells, the more GSE inhibits their growth and survival. On the other end of the disease spectrum, GSE leaves healthy cells alone entirely.

19 Jan 2013

New method may help predict response to chemotherapy for bowel cancer

Scientists at the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have developed a new method of predicting which patients with bowel (colorectal) cancer will respond effectively to chemotherapy. The results of this study are published in the current issue of the prestigious Cancer Research journal.

19 Jan 2013

New math model may help predict colon cancer resistance to chemotherapy

Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, a journal of the American Association for Cancer Research.

19 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.

17 Jan 2013

Iron oxide nanoparticles could help track transplanted human endothelial cells

A team of researchers from three medical institutions in Guangzhou, China, have found that iron oxide nanoparticles (INOPS) are a useful contrast agent for in vivo magnetic resonance tracking of transplanted human endothelial cells.

21 Dec 2012

Coffee habit improves survival chances with oral cancer

Drinking more than four cups of coffee per day lowers the risk for death from oral/pharyngeal cancer by almost half compared with drinking none, according to US study findings.

20 Dec 2012

Tumor cells manipulate unfolded protein response

Researchers at the University of California, San Diego School of Medicine report that tumor cells use stress signals to subvert responding immune cells, exploiting them to actually boost conditions beneficial to cancer growth.

19 Dec 2012

e-Therapeutics’ ETS2101 cancer trials on track

e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.

18 Dec 2012

Range of epigenetic immunoassays from VolitionRx now available for research use

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, announces the launch of NuQ, its range of research use only epigenetic immunoassays, to be available for sale at www.nucleosomics.com.

17 Dec 2012

Everolimus therapy might treat Myc-driven lymphoma

Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research.

15 Dec 2012

MDx, Amarantus sign license agreement for LymPro Alzheimer's disease diagnostic blood test

Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that it has licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, Inc.

14 Dec 2012

Scientists discover FAIM molecule as potential biomarker for bone marrow cancer

Singapore scientists have identified FAIM, a molecule that typically prevents cell death, as a potential biomarker to identify an incurable form of cancer in the bone marrow.

14 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012